Gilead Sciences is a large American biotechnology company that researches, develops, and sells medicines. Its recent lobbying focuses on health issues, especially prescription drug payment reform and the 340B drug discount program, and on supply chain matters. Filings show it spent about $320,000 and used the Todd Strategy Group to lobby Congress.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
DANIEL M TODD
The latest disclosures for this client.
TODD STRATEGY GROUP
Q1TODD STRATEGY GROUP
Q4The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
TODD STRATEGY GROUP
ERIC BERGREN
TODD STRATEGY GROUP
KATHERINE FLEMING COTTON
TODD STRATEGY GROUP
PAUL EDATTEL
TODD STRATEGY GROUP
TED LEHMAN
TODD STRATEGY GROUP
TAYLOR SEXTON
TODD STRATEGY GROUP
JEFF LUCAS
TODD STRATEGY GROUP
KIMBERLY LINTHICUM
TODD STRATEGY GROUP
TODD STRATEGY GROUP
Q3TODD STRATEGY GROUP
Q2TODD STRATEGY GROUP
Q1